The use of hepatitis C virus NS3/4A and secreted alkaline phosphatase to quantitate cell-cell membrane fusion mediated by severe acute respiratory syndrome coronavirus S protein and the receptor angiotensin-converting enzyme 2

Analytical Biochemistry

Volumn 366, Issue 2, 2007, Pages 190-196

  Chou, Chih Fong ^a   Shen, Shuo ^a   Mahadevappa, Geetha ^a   Lim, Seng Gee ^a   Hong, Wanjin ^a   Tan, Yee Joo ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

ACE2; EGFP; HCV; NS3 4A; SARS CoV; SEAP

Indexed keywords

CELL CULTURE; CELL MEMBRANES; GENES; PHOSPHATASES; RECOMBINANT PROTEINS; VIRUSES;

ACE2; EGFP; NS3/4A; SARS-COV; SEAP;

DISEASES;

ALKALINE PHOSPHATASE; ANGIOTENSIN CONVERTING ENZYME 2; CELL RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEINASE; RECOMBINANT PROTEIN; SECRETED ALKALINE PHOSPHATASE; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL FUSION; CELL MEMBRANE; CONTROLLED STUDY; CORONAVIRUS; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME RELEASE; FEMALE; HAMSTER; HEPATITIS C VIRUS; HUMAN; MEASUREMENT; MEMBRANE FUSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEVERE ACUTE RESPIRATORY SYNDROME;

CRICETULUS GRISEUS; HEPATITIS C VIRUS; SARS CORONAVIRUS;

EID: 34250322254     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.04.031     Document Type: Article

References (16)

1. Leabu M. Membrane fusion in cells: Molecular machinery and mechanisms. J. Cell Mol. Med. 10 (2006) 423-427
2. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science 300 (2003) 1399-1404
3. Li W., Wong S.K., Li F., Kuhn J.H., Huang I.C., Choe H., and Farzan M. Animal origins of the severe acute respiratory syndrome coronavirus: Insight from ACE2-S-protein interactions. J. Virol. 80 (2006) 4211-4219
4. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
5. Lip K.M., Shuo S., Yang X., Keng C.T., Zhang A., Oh J.H.L., et al. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J. Virol. 80 (2006) 941-950
6. Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A., et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87 (1996) 343-355
7. Lorenz I.C., Marcotrigiano J., Dentzer T.G., and Rice C.M. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442 (2006) 831-835
8. Chou C.F., Shen S., Tan Y.J., Fielding B.C., Tan T.H., Fu J.L., Xu Q.R., Lim S.G., and Hong W.J. A novel system reconstituting interaction between SARS-CoV S protein and its cellular receptor. J. Virol. Methods 123 (2005) 41-48
9. Lim S.P., Khu Y.L., Hong W.J., Tay A., Ting A.E., Lim S.G., and Tan Y.H. Identification and molecular characterization of the complete genome of a Singapore isolate of hepatitis C virus: Sequence comparison with other strains and phylogenetic analysis. Virus Genes 23 (2001) 89-95
10. Lee J.C., Shih Y.F., Hsu S.P., Chang T.Y., Chen L.H., and Hsu J.T. Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 316 (2003) 162-170
11. Cho Y.G., Yang S.H., and Sung Y.C. In vivo assay for hepatitis C viral serine protease activity using a secreted protein. J. Virol. Methods 72 (1998) 109-115
12. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
13. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
14. Lin C., Gates C.A., Rao B.G., Brennan D.L., Fulghum J.R., Luong Y.P., et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280 (2005) 36784-36791
15. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 70 (2006) 28-38
16. Yi M., Tong X., Skelton A., Chase R., Chen T., Prongay A., Bogen S.L., et al. a novel hepatitis C virus NS3/4A protease inhibitor: Reduced RNA replication fitness and partial rescue by second-site mutations. J. Biol. Chem. 281 (2006) 8205-8215